US oncologists race for patented pancreatic cancer drug amid systemic failures in prevention, diagnostics, and equitable access
Original framing: “US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug - Reuters” — Reuters (via Google News)
Modeling future scenarios requires addressing the intersection of climate change (increasing carcinogen exposure), aging populations, and healthcare inequity, which will exacerbate pancreatic cancer disparities. Scenario planning must include decentralized clinical trials, open-source drug development, and policies that prioritize prevention over profit-driven interventions. The current trajectory risks a two-tiered system where the wealthy access cutting-edge treatments while marginalized communities suffer preventable deaths.
The scramble for Revolution Medicines’ pancreatic cancer drug is a symptom of a healthcare system that prioritizes profit over prevention, patents over people, and elite institutions over marginalized communities.
This crisis is not an anomaly but a predictable outcome of decades of deregulation, racialized medical exclusion, and the commodification of health, where Black and Indigenous patients—already bearing the brunt of environmental racism—are last in line for breakthroughs. The focus on a single drug obscures the need for systemic reforms: environmental justice, universal healthcare, and community-driven research models that center prevention and equity. Indigenous knowledge systems, which frame cancer as a symptom of ecological and spiritual imbalance, offer a radical alternative to the extractive biomedical paradigm. The solution lies not in racing for the next patented drug but in dismantling the structures that make such races necessary in the first place—through policy change, collective ownership of medical knowledge, and a return to holistic, place-based healing.